Kora Saúde Participações Future Growth
Future criteria checks 3/6
Kora Saúde Participações is forecast to grow earnings and revenue by 85.3% and 6.5% per annum respectively. EPS is expected to grow by 85.9% per annum. Return on equity is forecast to be 5.3% in 3 years.
Key information
85.3%
Earnings growth rate
85.9%
EPS growth rate
| Healthcare earnings growth | 26.6% |
| Revenue growth rate | 6.5% |
| Future return on equity | 5.3% |
| Analyst coverage | Low |
| Last updated | 26 Nov 2024 |
Recent future growth updates
Recent updates
Kora Saúde Participações S.A.'s (BVMF:KRSA3) Shares Climb 26% But Its Business Is Yet to Catch Up
Nov 06
Returns On Capital Signal Tricky Times Ahead For Kora Saúde Participações (BVMF:KRSA3)
Oct 28Kora Saúde Participações S.A.'s (BVMF:KRSA3) Business And Shares Still Trailing The Industry
Sep 21Revenues Working Against Kora Saúde Participações S.A.'s (BVMF:KRSA3) Share Price Following 25% Dive
Jun 13Does Kora Saúde Participações (BVMF:KRSA3) Have A Healthy Balance Sheet?
May 23Why Investors Shouldn't Be Surprised By Kora Saúde Participações S.A.'s (BVMF:KRSA3) 26% Share Price Plunge
Apr 16Little Excitement Around Kora Saúde Participações S.A.'s (BVMF:KRSA3) Revenues As Shares Take 25% Pounding
Feb 06There Are Reasons To Feel Uneasy About Kora Saúde Participações' (BVMF:KRSA3) Returns On Capital
Jan 17Kora Saúde Participações S.A. (BVMF:KRSA3) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Dec 05Should You Investigate Kora Saúde Participações S.A. (BVMF:KRSA3) At R$1.17?
Sep 07Kora Saúde Participações' (BVMF:KRSA3) Returns On Capital Not Reflecting Well On The Business
Jul 24Returns On Capital Signal Tricky Times Ahead For Kora Saúde Participações (BVMF:KRSA3)
Jan 10Kora Saúde Participações S.A. (BVMF:KRSA3) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Apr 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,617 | 48 | 386 | N/A | 3 |
| 12/31/2025 | 2,464 | -25 | 361 | N/A | 3 |
| 12/31/2024 | 2,286 | -95 | 524 | N/A | 2 |
| 9/30/2024 | 2,276 | -91 | 2 | 65 | N/A |
| 6/30/2024 | 2,289 | -111 | 64 | 137 | N/A |
| 3/31/2024 | 2,272 | -145 | 110 | 200 | N/A |
| 12/31/2023 | 2,260 | -168 | -325 | -234 | N/A |
| 9/30/2023 | 2,233 | -212 | -137 | -48 | N/A |
| 6/30/2023 | 2,167 | -222 | -159 | -74 | N/A |
| 3/31/2023 | 2,121 | -173 | -314 | -195 | N/A |
| 12/31/2022 | 2,047 | -108 | 149 | 281 | N/A |
| 9/30/2022 | 1,923 | -122 | -300 | -158 | N/A |
| 6/30/2022 | 1,736 | -83 | -257 | -132 | N/A |
| 3/31/2022 | 1,524 | -62 | -168 | -57 | N/A |
| 12/31/2021 | 1,262 | -64 | -84 | 15 | N/A |
| 9/30/2021 | 1,029 | 14 | -65 | 8 | N/A |
| 6/30/2021 | 860 | 41 | -88 | 3 | N/A |
| 3/31/2021 | 689 | 28 | -52 | 5 | N/A |
| 12/31/2020 | 612 | 16 | -17 | 25 | N/A |
| 12/31/2019 | 442 | -3 | -70 | -53 | N/A |
| 12/31/2018 | 283 | 1 | -50 | -16 | N/A |
| 12/31/2017 | 264 | 6 | N/A | 11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KRSA3 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (10.4%).
Earnings vs Market: KRSA3 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: KRSA3 is expected to become profitable in the next 3 years.
Revenue vs Market: KRSA3's revenue (6.5% per year) is forecast to grow slower than the BR market (7.8% per year).
High Growth Revenue: KRSA3's revenue (6.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KRSA3's Return on Equity is forecast to be low in 3 years time (5.3%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 10:37 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kora Saúde Participações S.A. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Gustavo Miele | Goldman Sachs |
| Gustavo Miele | Itau BBA |